Literature DB >> 2182279

Radiation-induced lung injury.

R A Rosiello1, W W Merrill.   

Abstract

The use of radiation therapy is limited by the occurrence of the potentially fatal clinical syndromes of radiation pneumonitis and fibrosis. Radiation pneumonitis usually becomes clinically apparent from 2 to 6 months after completion of radiation therapy. It is characterized by fever, cough, dyspnea, and alveolar infiltrates on chest roentgenogram and may be difficult to differentiate from infection or recurrent malignancy. The pathogenesis is uncertain, but appears to involve both direct lung tissue toxicity and an inflammatory response. The syndrome may resolve spontaneously or may progress to respiratory failure. Corticosteroids may be effective therapy if started early in the course of the disease. The time course for the development of radiation fibrosis is later than that for radiation pneumonitis. It is usually present by 1 year following irradiation, but may not become clinically apparent until 2 years after radiation therapy. It is characterized by the insidious onset of dyspnea on exertion. It most often is mild, but can progress to chronic respiratory failure. There is no known successful treatment for this condition.

Entities:  

Mesh:

Year:  1990        PMID: 2182279

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  12 in total

1.  Differences in irradiated lung gene transcription between fibrosis-prone C57BL/6NHsd and fibrosis-resistant C3H/HeNHsd mice.

Authors:  Ronny Kalash; Hebist Berhane; Jeremiah Au; Byung Han Rhieu; Michael W Epperly; Julie Goff; Tracy Dixon; Hong Wang; Xichen Zhang; Darcy Franicola; Ashwin Shinde; Joel S Greenberger
Journal:  In Vivo       Date:  2014 Mar-Apr       Impact factor: 2.155

2.  Single-nucleotide polymorphisms of TGFβ1 and ATM associated with radiation-induced pneumonitis: a prospective cohort study of thoracic cancer patients in China.

Authors:  Ying Xiao; Xianglin Yuan; Hong Qiu; Qianxia Li
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 3.  Melatonin as an anti-inflammatory agent in radiotherapy.

Authors:  M Najafi; A Shirazi; E Motevaseli; A H Rezaeyan; A Salajegheh; S Rezapoor
Journal:  Inflammopharmacology       Date:  2017-03-02       Impact factor: 4.473

4.  Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality.

Authors:  E S Yi; S T Williams; H Lee; D M Malicki; E M Chin; S Yin; J Tarpley; T R Ulich
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

5.  Radiation-induced lung injury is mitigated by blockade of gastrin-releasing peptide.

Authors:  Shutang Zhou; Esther Nissao; Isabel L Jackson; Wei Leong; Lindsay Dancy; Frank Cuttitta; Zeljko Vujaskovic; Mary E Sunday
Journal:  Am J Pathol       Date:  2013-02-08       Impact factor: 4.307

6.  A dramatic case of genital radionecrosis.

Authors:  José Guzmán-Esquivel; Ivan Delgado-Enciso; Héctor Solano-Moreno
Journal:  Int Urol Nephrol       Date:  2009-05-31       Impact factor: 2.370

7.  Recall lung pneumonitis due to carmustine after radiotherapy.

Authors:  P S Thomas; S Agrawal; M Gore; D M Geddes
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

8.  Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma.

Authors:  Robin Cornelissen; Suresh Senan; Imogeen E Antonisse; Hauw Liem; Youke K Y Tan; Arjan Rudolphus; Joachim G J V Aerts
Journal:  Radiat Oncol       Date:  2007-01-03       Impact factor: 3.481

9.  The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.

Authors:  C Blomqvist; K Tiusanen; I Elomaa; P Rissanen; T Hietanen; E Heinonen; P Gröhn
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

10.  Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer.

Authors:  Vittorio Donato; Stefano Arcangeli; Alessia Monaco; Cristina Caruso; Michele Cianciulli; Genoveva Boboc; Cinzia Chiostrini; Roberta Rauco; Maria Cristina Pressello
Journal:  Front Oncol       Date:  2013-11-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.